Opthea Limited, a prominent clinical stage biopharmaceutical company from Australia, has recently gained attention for its revolutionary therapies primarily designed to combat eye diseases. The company relies on a robust intellectual property portfolio, with a focus on Vascular Endothelial Growth Factors (VEGF) including VEGF-C, VEGF-D, and VEGF Receptor-3, to develop cutting-edge treatments for diseases related to blood and lymphatic vessel growth and vascular leakage. Opthea's flagship product, OPT 302, is a soluble form of VEGFR 3 that is currently undergoing clinical trials as a highly innovative therapy for wet neovascular age-related macular degeneration and diabetic macular edema (DME). In addition, Opthea aims to leverage its impressive VEGF-C/D inhibitors to supplement VEGF-A inhibitors for the treatment of various retinal diseases, including wet neovascular AMD. Founded in 1984 and formerly known as Circadian Technologies Limited, Opthea Limited has established itself as a pioneering force in the healthcare industry, advancing fine-tuned techniques to treat debilitating eye conditions. The company's headquarters are located in South Yarra, Australia.